Paul B. Cleveland
Interim President and Chief Executive Officer
John A. Latham, Ph.D.
Chief Scientific Officer
Mark J. Litton, Ph.D., MBA
Chief Business Officer and Treasurer
Jeffrey T.L. Smith, M.D., FRCP
Managing Director, Alder BioPharmaceuticals Limited
Elisabeth A. Sandoval, MBA
Chief Commercial Officer and EVP Corporate Strategy
Executive Vice President and Principal Accounting Officer
James B. Bucher, J.D.
Senior Vice President and General Counsel
Senior Vice President, Pharmaceutical Operations
Senior Vice President, Quality
Prior to joining Alder as Vice President, Quality in 2015, Ms. Vahratian served as Principal Quality Consultant for ten years at AV BioPharma Consulting, serving the greater biopharmaceutical industry in support of innovator biologics drug development and regulatory product registrations. While at Immunex Corporation (now Amgen) from 1989 to 2002, Ms. Vahratian served as VP, Quality and various management positions, where she was instrumental in gaining FDA approval of Enbrel® and managing Enbrel® commercial operations at multiple sites worldwide. Ms. Vahratian supported Wyeth (now Pfizer) in their international registration of Enbrel® in the European Union. Ms. Vahratian has been involved in more than 15 IND applications and two FDA marketing authorization drug approvals. Ms. Vahratian holds a B.S. in Biology and Psychology from Hope College.